Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!
Researchers at CHOP are trying to improve outcomes in
the treatment of adolescents with anorexia nervosa. Eligible families will
receive Family Based Treatment for anorexia nervosa. Some adolescents with
anorexia nervosa will also receive Cognitive Remediation Therapy (a treatment
that increases flexible thinking). Both parents are required to participate and
any siblings living at home are asked to come to the first four treatment
sessions. Families will receive treatment for approximately 6 months and will
be asked to complete number of assessments during treatment and at two time
points after treatment ends.
The purpose of this research study is to look at whether or not
a sleep questionnaire can be used on infants 3 to 24 months of age, with or at
high-risk of having Cerebral Palsy. This questionnaire is currently being used
on older children, so we will be looking at a younger age group.
This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused. All participants enrolled in the study will receive the investigational medication.
We are currently enrolling individuals who meet the following criteria:*
Thalassemia and not receiving regular RBC transfusions (Cohort C)
There
are additional eligibility requirements, which the investigator will explain to
you.
This study involves taking a study drug called ALRN-6924. ALRN-6924
is an investigational cancer treatment that activates p53, which suppresses the
growth of tumors by blocking proteins in the cell called MDM2 and MDMX that
inhibit p53 from doing its job. The overall goals of this
study are to evaluate the side effects and benefits of ALRN-6924 in patients
with relapsed or treatment refractory solid tumor or brain tumor, and to determine
the best dose of ALRN-6924 for children and adolescents. This study will also
look at how the body breaks down ALRN-6924 by measuring the amount of ALRN-6924
in the blood over time after a dose.
The purpose of this study
is to determine the highest safe dose of abemaciclib in patients with relapsed
or treatment refractory solid tumors given in combination with the chemotherapy
drugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide
(Part B).
This study seeks to understand brain structural and functional development in typically developing infants. Participants will be asked to complete up to 7 visits to CHOP over time to complete an MRI and behavioral assessments. We hope our findings may contribute to future treatments for those with brain structural or functional differences. Participants will receive a small gift and be compensated for their time.
The Child and Adolescent Thyroid Consortium (CATC) Biorepository is a collaborative research program dedicated to studying thyroid cancers and other thyroid-related conditions. The goal of the CATC Biorepository is to address the unmet need of creating a well-annotated registry and bio specimen repository for patients with varying thyroid-related diagnoses. Collaborating clinicians and scientists are encouraged to use the specimens and infrastructure of the CATC Biorepository to make meaningful discoveries to help patients most at-risk.
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”). WU-CART-007 uses immune cells, called T cells, that are genetically changed to identify cancer cells. In this study, T cells are collected from a healthy human donor and have been modified in a laboratory. If the genetically changed T cells recognize and attach to cancer cells, they may have the ability to kill those cancer cells.
Patients with T-cell Acute Lymphoblatic Leukemia (T-ALL) or Lymphoblastic Lymphoma (LBL), where the disease has come back (relapsed) or has not responded to treatment (refractory) may be eligible for the study.
The ENERGY study is for adults (ages 18 and up) with warm Autoimmune Hemolytic Anemia (wAIHA) who are currently receiving treatment or have previously received treatment. The goal of the study is to see if the study drug, Nipocalimab is safe and effective in the treatment of wAIHA. Nipocalimab is an investigational medication designed to stop your immune system from destroying your red blood cells.
You may be able to join the study if you are:
Other study requirements will apply.
The goal of this study is to evaluate the safety and efficacy of an investigational drug called "Elamipretide" in adult patients with mitochondrial disease. "Investigational" means the study drug has not been approved by the U.S. Food and Drug Administration (FDA) and its use in this study is experimental.
The study will last for approximately 13 months and will include at least 7 outpatient visits at CHOP, where participants will be provided the study drug (randomized to active drug or placebo) and monitored for safety. The clinical trial also involves blood and urine tests, cardiac tests, physical exercise tests, and other study procedures. For more information: https://clinicaltrials.gov/ct2/show/NCT05162768
You will also receive travel support and reimbursement for related expenses.
Are you interested learning about opportunities to participate in research? Sign up to receive information about new research studies at CHOP. It’s a great way to support the work of the Research Institute.